156 related articles for article (PubMed ID: 22475985)
1. Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone.
Ling W; Hillhouse M; Jenkins J; Miotto K; Torrington M; Chapleo C
J Addict Med; 2012 Jun; 6(2):118-23. PubMed ID: 22475985
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
5. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.
Hay JL; La Vincente SF; Somogyi AA; Chapleo CB; White JM
Eur J Pain; 2011 Mar; 15(3):293-8. PubMed ID: 20728384
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
[TBL] [Abstract][Full Text] [Related]
8. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
9. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
[TBL] [Abstract][Full Text] [Related]
10. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
12. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine.
Upadhyay J; Anderson J; Baumgartner R; Coimbra A; Schwarz AJ; Pendse G; Wallin D; Nutile L; Bishop J; George E; Elman I; Sunkaraneni S; Maier G; Iyengar S; Evelhoch JL; Bleakman D; Hargreaves R; Becerra L; Borsook D
Neuroimage; 2012 Feb; 59(4):3762-73. PubMed ID: 22119647
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
15. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model.
Koppert W; Ihmsen H; Körber N; Wehrfritz A; Sittl R; Schmelz M; Schüttler J
Pain; 2005 Nov; 118(1-2):15-22. PubMed ID: 16154698
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
17. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
18. Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model.
Pade PA; Cardon KE; Hoffman RM; Geppert CM
J Subst Abuse Treat; 2012 Dec; 43(4):446-50. PubMed ID: 22980449
[TBL] [Abstract][Full Text] [Related]
19. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization.
Berland DW; Malinoff HL; Weiner MA; Przybylski R
Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313
[TBL] [Abstract][Full Text] [Related]
20. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
